Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.68 |
| ▸ | CTSS | P25774 | 2/20 | 0.61 |
| ▸ | CTSL | P07711 | 1/20 | 0.61 |
| ▸ | CTSB | P07858 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.61 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.61 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.61 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.61 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.61 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.61 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.58 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.58 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22962098 | 1.00 | REN (0.68) | RENCTSSCTSLCTSBCTSK | |
| SCHEMBL23106755 | 1.00 | REN (0.68) | RENCTSSCTSLCTSBCTSK | |
| SCHEMBL6857159 | 1.00 | REN (0.68) | RENCTSSCTSLCTSBCTSK | |
| SCHEMBL1913543 | 1.00 | REN (0.68) | RENCTSSCTSLCTSBCTSK | |
| SCHEMBL8073093 | 0.95 | REN (0.68) | RENCTSSCTSLCTSBCTSK | |
| SCHEMBL28376535 | 0.95 | REN (0.68) | RENCTSSCTSLCTSBCTSK | |
| SCHEMBL30789039 | 0.95 | REN (0.68) | RENCTSSCTSLCTSBCTSK | |
| SCHEMBL18171935 | 0.95 | REN (0.68) | RENCTSSCTSLCTSBCTSK | |
| SCHEMBL7319373 | 0.95 | REN (0.68) | RENCTSSCTSLCTSBCTSK | |
| SCHEMBL10880715 | 0.94 | REN (0.70) | RENCTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112552374-B | Preparation method of peptide amide compound and intermediate thereof | 西藏海思科制药有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-112552374-A | Preparation method of peptide amide compound and intermediate thereof | 四川海思科制药有限公司 | 2021-03-26 | — | — | CN | disclosed |
| US-10550150-B2 | Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist | CADILA HEALTHCARE LIMITED (IN) | 2020-02-04 | — | — | US | disclosed |
| US-10550150-B2 | Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist | CADILA HEALTHCARE LIMITED (IN) | 2020-02-04 | — | — | US | disclosed |
| CN-109563133-A | POLYAMIDE COMPOUND AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-04-02 | — | — | CN | disclosed |
| US-20180282369-A1 | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2018-10-04 | — | — | US | disclosed |
| EP-3294315-A2 | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA OPIOID RECEPTORS (KOR) AGONIST | Cadila Healthcare Limited (IN) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016181408-A2 | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST | CADILA HEALTHCARE LIMITED (IN) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550150-B2 | Short-chain peptides as Kappa (κ) opioid receptors (KOR) agonist | OPRK1, OPRL1, OPRD1 | REN 1342/4885CTSS 1924/4885CTSL 1783/4885 |
| US-20180282369-A1 | NOVEL SHORT-CHAIN PEPTIDES AS KAPPA (κ) OPIOID RECEPTORS (KOR) AGONIST | OPRK1, OPRL1, OPRD1 | REN 1556/4885CTSS 2139/4885CTSL 1857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.